Fig. 2

Celecoxib dose-dependently improves pain and inflammation on day 1 of MIA-induced model of OA. MIA-induced secondary allodynia was present on day 1 of the model. Systemic administration of CXB dose-dependently improved the hindpaw withdrawal threshold over a 240-min time course (a) (P < 0.0001; two-way ANOVA with Tukey post hoc test; ^##P < 0.01, ^#P < 0.05, *P < 0.05, ^$$P < 0.01, ^$P < 0.05, ^∇∇∇P < 0.001, ^∇∇P < 0.01, ^∇P < 0.05; n = 8). CXB dose-dependently decreased both rolling leukocytes (b) (P < 0.0001; one-way ANOVA with Tukey post hoc test; **P < 0.01; n = 8) and adherent leukocytes (c) (P < 0.0001; one-way ANOVA with Tukey post hoc test; ****P < 0.0001, **P < 0.01; n = 8) at 360 min post-drug administration. Data are mean values ± SEM. ANOVA, analysis of variance; BL, baseline; CXB, celecoxib; MIA, sodium monoiodoacetate; VEH, vehicle; ^#indicates post hoc comparison between 10 mg/kg and vehicle; *post hoc comparison between 3 and 10 mg/kg; ^∇post hoc comparison between 30 mg/kg and vehicle; ^$post hoc comparison between 3 and 30 mg/kg